Beyondspring Inc
BYSI2.190USD
+0.120+5.80%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
88.29MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Beyondspring Inc Unternehmen
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
Unternehmensinformationen
BörsenkürzelBYSI
Name des UnternehmensBeyondspring Inc
IPO-datumMar 09, 2017
CEODr. Lan Huang, Ph.D.
Anzahl der mitarbeiter40
WertpapierartOrdinary Share
GeschäftsjahresendeMar 09
Addresse100 Campus Drive, West Side, 4Th Floor
StadtFLORHAM PARK
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl07932
Telefon16465284184
Websitehttps://www.beyondspringpharma.com/en/
BörsenkürzelBYSI
IPO-datumMar 09, 2017
CEODr. Lan Huang, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Lan Huang, Ph.D.
Dr. Lan Huang, Ph.D.
Chairperson of the Board, Chief Executive Officer, Co-Founder
Chairperson of the Board, Chief Executive Officer, Co-Founder
4.26M
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Independent Director
Independent Director
53.86K
+119.03%
Dr. Jiangwen (Jen) Majeti, Ph.D.
Dr. Jiangwen (Jen) Majeti, Ph.D.
Independent Director
Independent Director
50.91K
--
Dr. June Lu, Ph.D.
Dr. June Lu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Sihai Xu
Mr. Sihai Xu
Director
Director
--
--
Mr. Brendan P. Delaney
Mr. Brendan P. Delaney
Independent Director
Independent Director
--
--
Mr. Matthew Kirkby
Mr. Matthew Kirkby
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Lan Huang, Ph.D.
Dr. Lan Huang, Ph.D.
Chairperson of the Board, Chief Executive Officer, Co-Founder
Chairperson of the Board, Chief Executive Officer, Co-Founder
4.26M
--
Mr. Patrick (Pat) Fabbio
Mr. Patrick (Pat) Fabbio
Independent Director
Independent Director
53.86K
+119.03%
Dr. Jiangwen (Jen) Majeti, Ph.D.
Dr. Jiangwen (Jen) Majeti, Ph.D.
Independent Director
Independent Director
50.91K
--
Dr. June Lu, Ph.D.
Dr. June Lu, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Sihai Xu
Mr. Sihai Xu
Director
Director
--
--
Mr. Brendan P. Delaney
Mr. Brendan P. Delaney
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 19
Aktualisiert: Sat, Jul 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Decheng Capital LLC
12.11%
Huang (Lan)
10.58%
Jia (Linqing)
4.43%
The Vanguard Group, Inc.
1.30%
BlackRock Institutional Trust Company, N.A.
0.29%
Other
71.30%
Aktionäre
Aktionäre
Anteil
Decheng Capital LLC
12.11%
Huang (Lan)
10.58%
Jia (Linqing)
4.43%
The Vanguard Group, Inc.
1.30%
BlackRock Institutional Trust Company, N.A.
0.29%
Other
71.30%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
15.26%
Venture Capital
12.11%
Investment Advisor
1.69%
Investment Advisor/Hedge Fund
0.35%
Hedge Fund
0.13%
Bank and Trust
0.09%
Research Firm
0.03%
Other
70.33%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
62
11.96M
29.67%
-626.00K
2025Q1
65
11.44M
28.38%
-1.18M
2024Q4
71
11.41M
28.30%
-5.42M
2024Q3
73
15.85M
39.34%
-1.46M
2024Q2
85
16.08M
39.89%
-939.10K
2024Q1
128
16.18M
41.46%
-1.22M
2023Q4
143
15.76M
40.39%
-1.74M
2023Q3
172
17.23M
44.26%
-3.36M
2023Q2
182
17.28M
44.39%
-4.16M
2023Q1
198
17.53M
45.04%
-4.14M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Decheng Capital LLC
4.88M
12.11%
-75.49K
-1.52%
Mar 31, 2025
Huang (Lan)
4.26M
10.58%
--
--
Feb 28, 2025
Jia (Linqing)
1.78M
4.43%
+4.00
+0.00%
Feb 28, 2025
BlackRock Institutional Trust Company, N.A.
115.97K
0.29%
-1.09K
-0.93%
Mar 31, 2025
BlackRock Financial Management, Inc.
90.54K
0.22%
--
--
Mar 31, 2025
Fabbio (Patrick)
53.86K
0.13%
+29.27K
+119.03%
Feb 28, 2025
Majeti (Jiangwen)
50.91K
0.13%
--
--
Feb 28, 2025
UBS Switzerland AG
34.93K
0.09%
-17.48K
-33.35%
Mar 31, 2025
Tanaka Capital Management, Inc.
26.30K
0.07%
-3.18K
-10.78%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
